Stereocomplexes for the delivery of anti-cancer agents
US-2024350644-A1 · Oct 24, 2024 · US
Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders
US8933071B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8933071-B2 |
| Application number | US-61399609-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 6, 2009 |
| Priority date | Nov 7, 2008 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases and disorders.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a patient having a proliferative blood or bone marrow disease or disorder, the method comprising administering to the patient an effective amount of a compound having a formula: wherein the proliferative blood or bone marrow disorder is selected from a group consisting of an Acute Megakaryoblastic Leukemia, a Myeloproliferative Disease, a Myelodysplastic Syndrome, and an Acute Myeloid Leukemia. 2. The method of claim 1 , wherein the effective amount is effective for inducing polyploidization of megakaryocyte cells in the patient, and the megakaryocyte cells are megakaryocyte progenitors. 3. The method of claim 1 , wherein the effective amount is effective for inducing polyploidization of megakaryocyte cells in the patient, and the megakaryocyte cells are immortalized or dysplastic cells. 4. The method of claim 1 , wherein the effective amount is effective for inducing polyploidization of megakaryocyte cells in the patient, and the megakaryocyte cells further are promoted to differentiate into platelet-producing cells. 5. The method of claim 1 , wherein the patient has an Acute Megakaryoblastic Leukemia selected from a group consisting of AMKL associated with mutagenesis of GATA1 in Down syndrome, pediatric AMKL associated with a (1:22) translocation, and adult AMKL associated with mutations in JAK2 or JAK3. 6. The method of claim 1 , wherein the patient has a Myeloproliferative Disease selected from a group consisting of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV). 7. The method of claim 1 , wherein the effective amount is effective for increasing platelet counts in the patient. 8. The method of claim 1 , wherein the compound haS a formula: 9. The method of claim 1 , wherein the compound has a formula: 10. A method for treating a patient having Acute Myeloid Leukemia, the method comprising administering to the patient an effective amount of a compound having a formula: 11. The method of claim 10 , wherein the compound has a formula: 12. The method of claim 10 , wherein the compound has a formula:
Assignees
Inventors
Classifications
- A61K31/5513Primary
1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8933071B2 cover?
- Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases and disorders.
- Who is the assignee on this patent?
- Crispino John D, Wen Qiang, Huang Zan, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5513. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).